Jacinto Solivellas de Oleza works at Olesis Management as a partner and senior board advisor. Beyond dedication to his clients, Jacinto Solivellas de Oleza supports leukemia research, having recently founded the Alexcar Leukaemia Foundation which cares for patients diagnosed with the disease.
Among recent developments in the fight against leukemia, one of the most promising has been documented in a study from the Johns Hopkins Kimmel Cancer Center that analyzed a new compound that eliminates leukemia cells. The study found that two daily doses of the compound TTT-3002 taken over the span of 10 days eliminated treatment-resistant leukemia cells from a group of mice. Additionally, the mice treated with the new drug survived around 100 days longer than non-treated mice and began experiencing normal bone marrow activity. In direct comparisons, the new treatment matched or bettered the performance of other leukemia drugs.
The study showed that the TTT-3002 compound is a very potent inhibitor of FLT3 gene mutation. While FLT3 genes normally produce an enzyme that replenishes bone marrow stem cells, they mutate in around 35 percent of acute myeloid leukemia patients, causing a treatment-resistant form of the disease. Results showed that the amount of TTT-3002 needed to stem mutations was around six times less than the inhibitor currently being tested in clinical trials.